Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer affiliate Medrad agrees to new study of Cotavance

Bayer affiliate Medrad agrees to new study of Cotavance

12th April 2010

Bayer affiliate Medrad has agreed to make one of its balloon catheter devices available for a potentially groundbreaking new combination study.

The new Definitive AR trial will use Medrad’s Cotavance peripheral drug-eluting balloon in conjunction with ev3’s SilverHawk and TurboHawk plaque excision systems to determine efficacy against lower extremity peripheral arterial disease.

This pilot study will take place in late 2010 and will involve up to 125 European patients, with both companies expressing hope that the combination will provide a new treatment option for a complex condition.

Medrad is also preparing to conduct further trials to support clinical approval of Cotavance, which uses Paccocath drug matrix technology developed by Bayer.

Kraig McEwen, senior vice-president of Medrad Interventional/Possis, added: “We are pleased to collaborate with ev3, a worldwide leader in atherectomy, on this important pilot study.”

Last month, Bayer entered into a new collaboration with Prometheus Laboratories which will see the companies develop a new oncology diagnostics platform.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.